Aztreonam is a beta-lactam antibiotic used to treat select aztreonam sensitive gram negative bacteria. A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum.
- Mechanism
- Curator reviewed
The bactericidal action of aztreonam results from the inhibition of bacterial cell wall synthesis due to a high affinity of aztreonam for penicillin binding protein 3 (PBP3). By binding to PBP3, aztreonam inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. It is possible that aztreonam interferes with an autolysin inhibitor.
- Primary indication
- For the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure infections, intra-abdominal infections, and gynecologic infections.Curator reviewed · 14 structured indications
- Formula / weight
- C13H17N5O8S2 · 435.433 g/mol (avg)
- First approval
- Canada, 2011 · United States, 2009 · European Union, 2016
- Code names
- Corus 1020 · SQ-26776
- Brand names
Resolves to
WZPBZJONDBGPKJ-VEHQQRBSSA-NSMILESC[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(=O)O)\C2=CSC([NH3+])=N2)C(=O)N1S([O-])(=O)=OWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Aztreonam, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account